litlas
Log inCreate account

Charles V. Pollack

Active 1994–2025

99
Papers
18,877
Citations
79
h-index
98
i10-index

Citations

Citations per year for Charles V. Pollack1952: 1 citations1995: 2 citations1996: 3 citations1997: 2 citations1998: 2 citations1999: 5 citations2000: 10 citations2001: 13 citations2002: 12 citations2003: 20 citations2004: 25 citations2005: 60 citations2006: 84 citations2007: 122 citations2008: 107 citations2009: 110 citations2010: 151 citations2011: 132 citations2012: 131 citations2013: 101 citations2014: 129 citations2015: 129 citations2016: 134 citations2017: 128 citations2018: 118 citations2019: 425 citations2020: 386 citations2021: 321 citations2022: 206 citations2023: 157 citations2024: 288 citations2025: 110 citations2026: 6 citations1953–1994: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,466 citing papers, 26.5% of this breakdownUnited Kingdom: 461 citing papers, 8.3% of this breakdownCanada: 332 citing papers, 6% of this breakdownGermany: 287 citing papers, 5.2% of this breakdownItaly: 281 citing papers, 5.1% of this breakdownFrance: 263 citing papers, 4.8% of this breakdownAustralia: 192 citing papers, 3.5% of this breakdownNetherlands: 189 citing papers, 3.4% of this breakdownSpain: 170 citing papers, 3.1% of this breakdownChina: 168 citing papers, 3% of this breakdownSweden: 155 citing papers, 2.8% of this breakdownSwitzerland: 133 citing papers, 2.4% of this breakdown
0%26.5%Other 25.9%

Institutions

Fields

  • Medicine90.9%
  • Biochemistry, Genetics and Molecular Biology2.5%
  • Health Professions1.5%
  • Engineering0.9%
  • Economics, Econometrics and Finance0.7%
  • Environmental Science0.5%
  • Other3%

Topics

  • Acute Myocardial Infarction Research10.1%
  • Atrial Fibrillation Management and Outcomes6.5%
  • Antiplatelet Therapy and Cardiovascular Diseases5%
  • Venous Thromboembolism Diagnosis and Management5%
  • Cardiac Imaging and Diagnostics4.1%
  • Coronary Interventions and Diagnostics3.5%
  • Other65.8%

Coauthors

All papers

Open in search
  1. Idarucizumab for Dabigatran Reversal — Full Cohort Analysis

    Authors: Charles V. Pollack, Paul Reilly, Joanne van Ryn, John W. Eikelboom, Stephan Glund, Richard A. Bernstein, Robert Dubiel, Menno V. Huisman, Elaine M. Hylek, CW Kam, Pieter W. Kamphuisen, Jörg Kreuzer, Jerrold H. Levy, Gordon Royle, Frank W. Sellke, Joachim Stangier, Thorsten Steiner, Peter Verhamme, Bushi Wang, Laura Young, Jeffrey I. Weitz - New England Journal of Medicine 2017 cited by 1,136

  2. Idarucizumab for Dabigatran Reversal

    Authors: Charles V. Pollack, Paul A. Reilly, John W. Eikelboom, Stephan Glund, Peter Verhamme, Richard A. Bernstein, Robert Dubiel, Menno V. Huisman, Elaine M. Hylek, Pieter W. Kamphuisen, Jörg Kreuzer, Jerrold H. Levy, Frank W. Sellke, Joachim Stangier, Thorsten Steiner, Bushi Wang, CW Kam, Jeffrey I. Weitz - New England Journal of Medicine 2015 cited by 1,454

  3. Clinical Characteristics, Management, and Outcomes of Patients Diagnosed With Acute Pulmonary Embolism in the Emergency Department

    Authors: Charles V. Pollack, Donald Schreiber, Samuel Z. Goldhaber, David Slattery, John Fanikos, Brian J. O’Neil, James Thompson, Brian Hiestand, Beau Briese, Robert C. Pendleton, Chadwick D. Miller, Jeffrey A. Kline - Journal of the American College of Cardiology 2011 cited by 542

  4. Baseline Risk of Major Bleeding in Non–ST-Segment–Elevation Myocardial Infarction

    Authors: Sumeet Subherwal, Richard G. Bach, Anita Y. Chen, Brian F. Gage, Sunil V. Rao, L. Kristin Newby, Tracy Y. Wang, W. Brian Gibler, E. Magnus Ohman, Matthew T. Roe, Charles V. Pollack, Eric D. Peterson, Karen P. Alexander - Circulation 2009 cited by 991

  5. Platelet Inhibition with Cangrelor in Patients Undergoing PCI

    Authors: Robert A. Harrington, Gregg W. Stone, Steven E. McNulty, Harvey D. White, A. Michael Lincoff, C. Michael Gibson, Charles V. Pollack, Gilles Montalescot, Kenneth W. Mahaffey, Neal S. Kleiman, Shaun G. Goodman, Maged Amine, Dominick J. Angiolillo, Richard C. Becker, Derek P. Chew, William J. French, F Leisch, Keyur Parikh, Simona Skerjanec, Deepak L. Bhatt - New England Journal of Medicine 2009 cited by 618

  6. Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia

    Authors: Eiichiro Kanda, Anjay Rastogi, Toyoaki Murohara, Eva Lesén, Abiy Agiro, Matthew Arnold, Gengshi Chen, Toshitaka Yajima, Krister Järbrink, Charles V. Pollack - BMC Nephrology 2023 cited by 51

  7. Intravenous Platelet Blockade with Cangrelor during PCI

    Authors: Deepak L. Bhatt, A. Michael Lincoff, C. Michael Gibson, Gregg W. Stone, Steven E. McNulty, Gilles Montalescot, Neal S. Kleiman, Shaun G. Goodman, Harvey D. White, Kenneth W. Mahaffey, Charles V. Pollack, Steven V. Manoukian, Petr Widimský, Derek P. Chew, Fernando Cura, Ivan H Manukov, František Toušek, M. Zubair Jafar, Jaspal Arneja, Simona Skerjanec, Robert A. Harrington - New England Journal of Medicine 2009 cited by 643

  8. Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers

    Authors: Deepak L. Bhatt, Charles V. Pollack, Jeffrey I. Weitz, Lisa K. Jennings, Sherry L. Xu, Susan Arnold, Bret R. Umstead, Michael C. Mays, John S. Lee - New England Journal of Medicine 2019 cited by 135

  9. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial

    Authors: Gilles Montalescot, Uwe Zeymer, Johanne Silvain, Bertrand Boulanger, Marc Cohen, Patrick Goldstein, Patrick Ecollan, X. Combes, Kurt Huber, Charles V. Pollack, Jean-François Bénezet, Olivier Stibbe, Emmanuelle Filippi, Emmanuel Teíger, Guillaume Cayla, Simon Elhadad, Frédéric Adnet, Tahar Chouihed, S. Gallula, Agnès Greffet, Mounir Aout, Jean‐Philippe Collet, Éric Vicaut - The Lancet 2011 cited by 322

  10. Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial

    Authors: Michael D. Ezekowitz, Charles V. Pollack, Jonathan L. Halperin, Richard D. England, Sandra VanPelt Nguyen, Judith Spahr, Maria Sudworth, Nilo B. Cater, Andrei Breazna, Jonas Oldgren, Paulus Kirchhof - European Heart Journal 2018 cited by 172

  11. 2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants

    Authors: Gordon F. Tomaselli, Kenneth W. Mahaffey, Adam Cuker, Paul P. Dobesh, John Doherty, John W. Eikelboom, Roberta Florido, William J. Hucker, Roxana Mehran, Steven R. Messé, Charles V. Pollack, Fátima Rodríguez, Ravi Sarode, Deborah Siegal, Barbara S. Wiggins - Journal of the American College of Cardiology 2017 cited by 347

  12. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis

    Authors: Johanne Silvain, Farzin Beygui, Olivier Barthélémy, Charles V. Pollack, Mauricio G. Cohen, Uwe Zeymer, Kurt Huber, Patrick Goldstein, Guillaume Cayla, Jean Collet, Éric Vicaut, Gilles Montalescot - BMJ 2012 cited by 221

  13. EP-7041, a Factor XIa Inhibitor as a Potential Antithrombotic Strategy in Extracorporeal Membrane Oxygenation: A Brief Report

    Authors: Charles V. Pollack, Michael A. Kurz, Neil J. Hayward - Critical Care Explorations 2020 cited by 44

  14. Number of Coronary Heart Disease Risk Factors and Mortality in Patients With First Myocardial Infarction

    Authors: John G. Canto, Catarina I. Kiefe, William J. Rogers, Eric D. Peterson, Paul D. Frederick, William J. French, C. Michael Gibson, Charles V. Pollack, Joseph P. Ornato, Robert J. Zalenski, Jan Penney, Alan J. Tiefenbrunn, Philip Greenland, for the NRMI Investigators - JAMA 2011 cited by 261

  15. Developing a Decision Instrument to Guide Computed Tomographic Imaging of Blunt Head Injury Patients

    Authors: William R. Mower, Jerome R. Hoffman, Mel Herbert, Allan B. Wolfson, Charles V. Pollack, Michael I. Zucker - The Journal of Trauma: Injury, The Journal of Trauma: Injury, Infection, and Critical Care 2005 cited by 209

  16. Adverse drug reactions and drug–drug interactions with over-the-counter NSAIDs

    Authors: Nicholas Cooney, Charles V. Pollack, Paul Butkerait - Therapeutics and Clinical Risk Management 2015 cited by 208

  17. Frequency and Consequences of Recording an Electrocardiogram >10 Minutes After Arrival in an Emergency Room in Non–ST-Segment Elevation Acute Coronary Syndromes (from the CRUSADE Initiative)

    Authors: Deborah B. Diercks, W. Frank Peacock, Brian Hiestand, Anita Y. Chen, Charles V. Pollack, J. Douglas Kirk, Sidney C. Smith, W. Brian Gibler, E. Magnus Ohman, Andra L. Blomkalns, L. Kristin Newby, Judith S. Hochman, Eric D. Peterson, Matthew T. Roe - The American Journal of Cardiology 2005 cited by 119

  18. Bentracimab for Ticagrelor Reversal in Patients Undergoing Urgent Surgery

    Authors: Deepak L. Bhatt, Charles V. Pollack, C. David Mazer, Dominick J. Angiolillo, Philippe Gabríel Steg, Stefan James, Jeffrey I. Weitz, Rohit Ramnath, Susan Arnold, Michael C. Mays, Bret R. Umstead, Barbara White, Lisa Hickey, Lisa K. Jennings, Benjamin J. Curry, John S. Lee, Subodh Verma - NEJM Evidence 2021 cited by 56

  19. Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding

    Authors: Sake J. van der Wall, Renato D. Lópes, James Aisenberg, Paul A. Reilly, Joanne van Ryn, Stephan Glund, Amelie Elsaesser, Frederikus A. Klok, Charles V. Pollack, Menno V. Huisman - Circulation 2019 cited by 48

  20. Anticoagulant Reversal Strategies in the Emergency Department Setting: Recommendations of a Multidisciplinary Expert Panel

    Authors: Christopher W. Baugh, Michael P. Levine, David Cornutt, Jason Wilson, Richard Kwun, Charles E. Mahan, Charles V. Pollack, Evie G. Marcolini, Truman J. Milling, W. Frank Peacock, Rachel Rosovsky, Fred Wu, Ravi Sarode, Alex C. Spyropoulos, Todd C. Villines, Timothy Woods, John McManus, James M. Williams - Annals of Emergency Medicine 2019 cited by 91

  21. Real-World Modifications of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Hyperkalemia Initiating Sodium Zirconium Cyclosilicate Therapy: The OPTIMIZE I Study

    Authors: Abiy Agiro, Amin AN, Erin Cook, Fan Mu, Jingyi Chen, Pooja Desai, Yemmie Oluwatosin, Charles V. Pollack - Advances in Therapy 2023 cited by 25

  22. Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes

    Authors: Deepak L. Bhatt, Eric D. Peterson, Robert A. Harrington, Fang‐Shu Ou, Christopher P. Cannon, C. Michael Gibson, Neal S. Kleiman, Ralph G. Brindis, W. Frank Peacock, S. Brener, Venu Menon, Sidney C. Smith, Charles V. Pollack, W. Brian Gibler, E. Magnus Ohman, M. T. Roe, for the CRUSADE Investigators - European Heart Journal 2009 cited by 199

  23. Trends in presenting characteristics and hospital mortality among patients with ST elevation and non-ST elevation myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006

    Authors: William J. Rogers, Paul D. Frederick, Edna Stoehr, John G. Canto, Joseph P. Ornato, C. Michael Gibson, Charles V. Pollack, Joel M. Gore, Nisha Chandra‐Strobos, Eric D. Peterson, William J. French - American Heart Journal 2008 cited by 421

  24. Association of intravenous morphine use and outcomes in acute coronary syndromes: Results from the CRUSADE Quality Improvement Initiative

    Authors: Trip J. Meine, Matthew T. Roe, Anita Y. Chen, Manesh R. Patel, Jeffrey B. Washam, E. Magnus Ohman, W. Frank Peacock, Charles V. Pollack, W. Brian Gibler, Eric D. Peterson - American Heart Journal 2005 cited by 307